Overview on Essential Thrombocythemia and Polycythemia Vera Management

By Naveen Pemmaraju, MD;John Mascarenhas, MD;Ruben Mesa, MD;Jeanne M. Palmer, MD;Stephen Oh, MD, PhD
Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.
Posted in Uncategorized.

Leave a Reply

Your email address will not be published. Required fields are marked *